Showing 461-470 of 7113 results for "".
DWTV Extra: Skin and Scalp Health
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-skin-and-scalp-health/54147/Chesahna Kindred, MD, MBA, FAAD, discusses an event at the Science of Skin & Scalp Studio in New York, New York, featuring interactive rooms led by dermatologists, beauty experts, and influencers living with chronic inflammatory conditions sharing stories and shaping the conversation around skinDermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urDWTV Extra: Psoriasis Advocacy
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-psoriasis-advocacy/39890/International Federation of Psoriasis Associations (IFPA) executive director Frida Dunger discusses her organization's efforts to raise awareness, including a recent event involving the United Nations as well as World Psoriasis Day on October 29.DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aDermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://reachmd.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privDWTV Extra: Spotlight on Leadership
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-spotlight-on-leadership/54267/Practical Dermatology Editorial Board member Jennifer Soung, MD, discusses the LEADDerm meeting that she founded and why it is different from other conferences in dermatology.DWTV Extra: GPP Awareness Day
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-gpp-awareness-day/36704/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, discusses the importance of educating more clinicians about generalized pustular psoriasis (GPP) and observing GPP Awareness Day on August 13.Nemluvio Shows Efficacy in AD
https://practicaldermatology.com/series/dermwire-tv/nemluvio-shows-efficacy-in-ad/36134/In this episode of DermwireTV, Nemluvio (nemolizumab) showed efficacy in atopic dermatitis in recent studies; strontium cream helps manage pruritus in hidradenitis suppurativa (HS); and Lisa Swanson and Peter Lio get viewers up to date on dupilumab’s effectiveness at halting atopic march.Rosacea Comorbidities and Skincare with Energy-Based Devices
https://reachmd.com/programs/practical-dermatology/rosacea-comorbidities-and-skincare-with-energy-based-devices/35895/Ted Lain, MD, MBA, discusses the gut-skin connection as it relates to rosacea, as well as skincare with energy-based devices, at Music City SCALE 2025.